Mateos, Marķa-Victoria <br/><br/>
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.  [electronic resource] 

 -  Haematologica  Apr 2008 
 - 560-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.12106  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers, Tumor--analysis<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Follow-Up Studies<br/>Gastrointestinal Diseases--chemically induced<br/>Hematologic Diseases--chemically induced<br/>Humans<br/>Karnofsky Performance Status<br/>Male<br/>Melphalan--administration & dosage<br/>Multiple Myeloma--drug therapy<br/>Prednisone--administration & dosage<br/>Prognosis<br/>Pyrazines--administration & dosage<br/>Survival Analysis